Zulema sells GWPH 92.27: Equities analysts expect that GW Pharmaceuticals PLC- will post ($3.70) EPS for the current year.

The firm had revenue of $13.55 million for the quarter, compared to analyst estimates of $12.82 million. They set an overweight rating and a $150.00 price objective on the stock. Piper Jaffray reaffirmed a buy rating and issued a $147.00 target price on shares of GW Pharmaceuticals PLC- in a report on Tuesday, September 15th. Leerink Swann reiterated a buy rating and set a $135.00 price target on shares of GW Pharmaceuticals PLC- in a research note on Tuesday, September 15th. A number of other equities research analysts have also weighed in on GWPH.


Stephania:
Analysts anticipate that GW Pharmaceuticals PLC- will post ($3.70) earnings per share for the current year.

McKenzie:
During the same quarter in the previous year, the company earned ($0.03) earnings per share.

Teisha:
GW Pharmaceuticals PLC- (NASDAQ:GWPH) last posted its quarterly earnings results on Thursday, August 6th.

Dinorah:
Shares of GW Pharmaceuticals PLC- ( NASDAQ:GWPH ) traded down 1.07% during midday trading on Tuesday, hitting $112.54. 165,383 shares of the stock traded hands.

Marcelle:
This patent provides exclusivity until March 2029. An additional patent has been filed based on the findings from this study.

Genevieve:
This research showed CBD to have notable anti-psychotic effects in accepted pre-clinical models of schizophrenia, and also provides indicators that there is potential to enhance the effect of CBD with additional cannabinoids.

Eugenia:
This trial followed extensive pre-clinical research conducted by GW since 2007 into the effects of cannabinoids in psychiatric disease.

Louie:
The multi-center, double-blind, placebo-controlled trial enrolled a total of 88 patients who were treated over a period of six weeks.

Ana:
These provide insight into the differential effects of CBD in combination with specific anti-psychotic medications, as well as the nature of endpoints that are most responsive to cannabinoid treatment.

Kenia:
A series of sub-group analyses have been performed to identify predictors for a successful outcome to treatment with CBD in this challenging patient population.

Gw Pharmaceuticals Plc Ads (NASDAQ:GWPH)
//stockhand.net/us/?q=nasdaq%3Agwph&id=582010